SI
ADMS

SCP Investment’s Adamas Pharmaceuticals ADMS Stock Holding History

SCP Investment’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-30,000
Closed -$213K – 81
2019
Q1 		$213K Sell
30,000
-83,691
-74% -$753K 0.14% 56
2018
Q4 		$971K Sell
113,691
-174,494
-61% -$2.27M 0.89% 20
2018
Q3 		$5.77M Buy
288,185
+77,994
+37% +$1.83M 4.67% 8
2018
Q2 		$5.43M Buy
210,191
+9,732
+5% +$269K 2.69% 11
2018
Q1 		$4.79M Buy
200,459
+99,800
+99% +$3.15M 3.17% 7
2017
Q4 		$3.41M Buy
+100,659
New +$2.81M 3.53% 9

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCP Investment's ADMS Position: Q2 2019 in Review

SCP Investment sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 30,000 shares — an estimated $213K sold.

SCP Investment first reported a position in ADMS in Q4 2017 and held it in 6 quarters. The position peaked at $5.77M in Q3 2018. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • SCP Investment reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • SCP Investment sold 30,000 Adamas Pharmaceuticals shares in Q2 2019, an estimated $213K.
  • SCP Investment first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • SCP Investment's Adamas Pharmaceuticals position peaked at $5.77M in Q3 2018.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on SCP Investment's 13F filing for Q2 2019, filed 6 Aug 2019.